ES3060762T3 - Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis - Google Patents

Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis

Info

Publication number
ES3060762T3
ES3060762T3 ES16849389T ES16849389T ES3060762T3 ES 3060762 T3 ES3060762 T3 ES 3060762T3 ES 16849389 T ES16849389 T ES 16849389T ES 16849389 T ES16849389 T ES 16849389T ES 3060762 T3 ES3060762 T3 ES 3060762T3
Authority
ES
Spain
Prior art keywords
rapamycin
cells
approximately
mitochondrial
nrti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16849389T
Other languages
English (en)
Spanish (es)
Inventor
Christian Sell
Timothy Nacarelli
Ashley Azar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drexel University
Original Assignee
Drexel University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drexel University filed Critical Drexel University
Application granted granted Critical
Publication of ES3060762T3 publication Critical patent/ES3060762T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16849389T 2015-09-24 2016-09-19 Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis Active ES3060762T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562232228P 2015-09-24 2015-09-24
PCT/US2016/052442 WO2017053222A1 (en) 2015-09-24 2016-09-19 Novel compositions and methods for treating or preventing dermal disorders

Publications (1)

Publication Number Publication Date
ES3060762T3 true ES3060762T3 (en) 2026-03-30

Family

ID=58387119

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16849389T Active ES3060762T3 (en) 2015-09-24 2016-09-19 Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis

Country Status (9)

Country Link
US (4) US10695326B2 (cg-RX-API-DMAC7.html)
EP (2) EP3352755B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018528236A (cg-RX-API-DMAC7.html)
KR (1) KR20180081501A (cg-RX-API-DMAC7.html)
CN (2) CN108348508A (cg-RX-API-DMAC7.html)
AU (1) AU2016325446B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037469C (cg-RX-API-DMAC7.html)
ES (1) ES3060762T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017053222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
WO2017053222A1 (en) * 2015-09-24 2017-03-30 Drexel University Novel compositions and methods for treating or preventing dermal disorders
US20190167649A1 (en) * 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
EP3863606A4 (en) * 2018-10-11 2022-07-20 Drexel University METHODS OF TREATMENT OR PREVENTION OF SKIN DISEASES
JP7516252B2 (ja) * 2018-11-02 2024-07-16 株式会社 資生堂 オルタナティブオートファジー誘導剤を含む紫外線起因性炎症抑制剤
KR102132921B1 (ko) * 2018-12-13 2020-07-13 영남대학교 산학협력단 조타로리무스를 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
AU2020277132B1 (en) 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20040180430A1 (en) 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
US7026374B2 (en) 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
US20050250805A1 (en) * 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical ointment formulations
KR20070121746A (ko) 2005-03-14 2007-12-27 매크로켐 코포레이션 사람 피부를 통한 마크롤라이드 침투의 개선
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
MXPA06008797A (es) * 2006-08-03 2008-02-04 Fernando Ahumada Ayala Preparacion topica para el tratamiento de enfermedades inflamatorias de la piel que contiene sirolimus.
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2155146A4 (en) 2007-05-15 2012-11-21 Puretech Ventures METHOD AND COMPOSITIONS FOR TREATING SKIN TREATMENTS
WO2009046436A1 (en) * 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells
WO2010056778A1 (en) * 2008-11-11 2010-05-20 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
AU2013204219B2 (en) * 2009-04-10 2015-05-07 Haiyan Qi Novel anti-aging agents and methods to identify them
WO2010118419A2 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2011079154A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
JP5652795B2 (ja) * 2011-01-31 2015-01-14 国立大学法人大阪大学 皮膚疾患を処置するための外用薬およびその製造方法
WO2012142145A1 (en) 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CN104080786A (zh) * 2011-11-08 2014-10-01 因特利凯有限责任公司 使用多种药剂的治疗方案
WO2014004692A1 (en) 2012-06-26 2014-01-03 Sarah Bacus Compositions and methods for treatment vitiligo
US9296733B2 (en) * 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EA201690987A1 (ru) * 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
US9980976B2 (en) * 2015-02-17 2018-05-29 Northwestern University Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
WO2017053222A1 (en) 2015-09-24 2017-03-30 Drexel University Novel compositions and methods for treating or preventing dermal disorders

Also Published As

Publication number Publication date
AU2016325446B2 (en) 2021-05-13
US20200281903A1 (en) 2020-09-10
JP7573078B2 (ja) 2024-10-24
US20180280362A1 (en) 2018-10-04
JP7332666B2 (ja) 2023-08-23
JP2018528236A (ja) 2018-09-27
EP3352755B1 (en) 2025-12-24
US10695326B2 (en) 2020-06-30
CN108348508A (zh) 2018-07-31
KR20180081501A (ko) 2018-07-16
US11179374B2 (en) 2021-11-23
CN115645534A (zh) 2023-01-31
CA3037469A1 (en) 2017-03-30
US20260224540A1 (en) 2026-08-06
JP2022009168A (ja) 2022-01-14
AU2016325446A1 (en) 2018-04-19
WO2017053222A1 (en) 2017-03-30
EP3352755A1 (en) 2018-08-01
CA3037469C (en) 2024-04-16
EP4729121A3 (en) 2026-06-24
EP3352755A4 (en) 2019-04-03
HK1258696A1 (en) 2019-11-15
EP4729121A2 (en) 2026-04-22
US20220031673A1 (en) 2022-02-03
JP2023154020A (ja) 2023-10-18

Similar Documents

Publication Publication Date Title
US11179374B2 (en) Compositions and methods for treating or preventing dermal disorders
US20240108645A1 (en) Senescence and senescence associated secretory phenotype
US9555034B2 (en) Compositions and methods for treating skin cancer associated diseases
Thakur et al. Vitiligo: translational research and effective therapeutic strategies
WO2013188848A2 (en) Antiviral compounds and methods of use
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
WO2023096935A1 (en) Formulations of pyrrolopyridine-aniline compounds
ES2983061T3 (es) Combinación de terapias locales y sistémicas para mejorar el tratamiento de afecciones dermatológicas
US20250275974A1 (en) Treatment of frontal fibrosing alopecia
HK1258696B (en) Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis
US20230255945A1 (en) Formulations of pyrrolopyridine-aniline compounds
US12582649B2 (en) Compositions and methods for hair follicle regeneration
US11759434B2 (en) Methods and compositions for treating melanoma and non-melanoma skin cancers
KR101540051B1 (ko) 피부 노화 방지 또는 피부 상태 개선용 조성물
EP3804719A1 (en) Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy
US20210379026A1 (en) Methods for treating or preventing skin conditions
López Fauqued Preclinical Study of PI3K and BRAF Inhibitors in Malignant Melanoma/Estudio preclínico de inhibidores de PI3K y BRAF en melanoma maligno